Skip to content
Skip to footer
'); Ontada
Contact Us
Search
Search
Solutions
Providers
Life Sciences
Company
Careers
News & Insights
Publications
Providers
Life Sciences
Company
Careers
News & Insights
Publications
More
Publications Archive
Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer
July 10, 2023
Real-World Outpatient Cost of Care among Patients with Metastatic, Castrate-resistant Prostate Cancer
June 27, 2023
Assessment of Genomic Profiling in Colorectal Cancer Patients Treated in Community Oncology Practices
June 27, 2023
Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study
June 04, 2023
The impact of social determinants of health (SDOH) on use of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting
June 04, 2023
Social determinants of health and utilization of neoadjuvant chemotherapy in patients with triple negative breast cancer (TNBC) in the community oncology setting
June 04, 2023
Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting
June 03, 2023
Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy
June 03, 2023
Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets
June 02, 2023
Real world treatment patterns and survival by germline BRCA (gBRCA) mutation status in patients with HER2-negative early breast cancer (eBC) in the US community oncology setting: A retrospective observational study
June 02, 2023
Comparison of real-world mortality data among patients with glioblastoma (GBM) and metastatic pancreatic cancer (mPC) treated in the community oncology setting
June 02, 2023
Impact of social determinants of health (SDOH) measures on prescribing advanced androgen blockade (AAB) in patients with metastatic hormone sensitive prostate cancer (mHSPC)
June 02, 2023
Factors associated with platinum sensitivity (PST) and related outcomes in patients with ovarian cancer (OC) in a US community oncology setting: Looking beyond
June 02, 2023
Feasibility of Using Oncology-Specific Electronic health record (EHR) Data to Emulate Clinical Trial Eligibility Criteria
May 05, 2023
Mapping the flow of biomarker testing information, from test order through impact on treatment decision-making: a case study in mNSCLC
May 03, 2023
The Utility of “Single Exposure” versus Causal Architecture Approaches in Real-World Research
May 03, 2023
Assessing the Quality of Real-World Data and Real-World Evidence in Oncology Research: A Cohesive Framework for Researchers
May 03, 2023
Real-World Outpatient Cost of Care among Patients with Melanoma Treated in the US Community
May 03, 2023
Real-World Outpatient Cost of Care among Patients with Non-small Cell Lung Cancer (NSCLC) Treated in the US Community
May 03, 2023
Considerations for common exclusion criteria in real-world (RW) retrospective observational studies in oncology
May 03, 2023
Understanding the value of chart abstraction for assessing oral treatment history in the oncology outpatient setting
May 03, 2023
Patient (pt) characteristics, diagnostic journey, and cancer enrichment among pts with nonspecific signs and/or symptoms (s/sx) in the US community oncology setting: a real-world retrospective study
April 14, 2023
Symptomatology and Diagnostic Journey of Patients Diagnosed with Systemic Mstocytosis in The US Oncology Network
February 24, 2023
Real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval
February 16, 2023
Real-world treatment patterns and clinical outcomes for metastatic renal carcinoma in the current treatment era
February 06, 2023
Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment
February 01, 2023
Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
December 20, 2022
Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study
December 10, 2022
Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings
November 15, 2022
Real-world treatment patterns and clinical outcomes in patients with metastatic NSCLC after receiving first-line pembrolizumab with pemetrexed/platinum chemotherapy in the US oncology network
November 08, 2022
Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics
November 08, 2022
Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs ipilimumab + nivolumab
November 04, 2022
Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 3022 Patients With Polycythemia Vera (PV) Treated in US Community Practices
October 22, 2022
Relationship between recurrence/recurrence-free survival (RFS) and overall survival (OS) in patients with stage IIB and IIC melanoma following complete resection
October 17, 2022
Comparing Trial and Real-world Adjuvant Oxaliplatin Delivery in Patients With Stage III Colon Cancer Using a Longitudinal Cumulative Dose
October 13, 2022
Effectiveness of Azacitidine in Frontline Higher-Risk Myelodysplastic Syndrome: A Retrospective Cohort Study of 382 Patients
October 13, 2022
Oncology Drug Effectiveness from Electronic Health Record Data Calibrated Against RCT Evidence: The PARSIFAL Trial Emulation
October 10, 2022
Trilaciclib Use and Chemotherapy-Induced Myelosuppression Among Patients with ES- SCLC in US Community Oncology Settings
October 07, 2022
Oncology-specific Qualified Clinical Data Registry (QCDR) measures to advance cancer care and achieve Merit-Based Incentive Payment System (MIPS) performance
September 30, 2022
Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) in the United States
September 10, 2022
Treatment patterns and outcomes in metastatic synovial sarcoma: a real-world study in the US oncology network
August 26, 2022
Real-World Treatment Patterns and Outcomes Among Unresectable Stage III Non-Small Cell Lung Cancer Patients Initiating Chemoradiotherapy
August 06, 2022
Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: a US community oncology-based analysis.
July 30, 2022
Real-World Nivolumab Dosing Patterns and Safety Outcomes in Patients Receiving Adjuvant Therapy for Melanoma
July 25, 2022
Impact of COVID-19 Pandemic on Non-Small Cell Lung Cancer Care
June 02, 2022
Real-world (RW) treatment patterns and clinical outcomes for chemotherapy-based regimens in first line (1L) MSI-H/dMMR metastatic colorectal cancer (mCRC)
June 02, 2022
Blood monocyte and lymphocyte counts versus patient outcomes in non-small cell lung cancer after immune checkpoint inhibitor therapy: real-world data of 12,416 pts.
June 02, 2022
Impact of oncology clinical pharmacist intervention on clinical trial enrollment in The US Oncology Network ’s MYLUNG Consortium
June 02, 2022
Predictors of biomarker testing among patients (pts) with metastatic non-small cell lung cancer (mNSCLC)
June 02, 2022
Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 3022 Patients (Pts) With Polycythemia Vera (PV) Treated in US Community Practices
June 02, 2022
Real-world progression-free and overall survival for patients with advanced ovarian cancer utilizing PARP inhibitor second-line maintenance therapy vs active surveillance.
June 02, 2022
Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer
May 23, 2022
Integrating Data from Disparate Sources to Create a Comprehensive Patient Journey: A Case Study in Prostate Cancer
May 17, 2022
Frequency of and testing patterns for Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (DMMR) among solid tumors in a US community oncology setting
May 17, 2022
HER2 and Other Biomarker Testing Patterns Among Patients with Advanced Gastric Cancer (GC) or Gastric Esophageal Junction Cancer (GEJC)
May 17, 2022
Feasibility of Using Oncology Specific Electronic Health Records (EHR) Data to Emulate Clinical Trial Inclusion and Exclusion Criteria
May 17, 2022
Application of Medication History for Comorbidity Assessment in Cancer Patients
May 16, 2022
A Proposed Framework for Evaluating Continuity of Data Coverage in Electronic Health Record and Administrative Claims Data in Real-World Evidence (RWE) Studies
May 16, 2022
Lack of Standardization in Quantitative Evaluations of the Efficacy-Effectiveness Gap (EEG) for Cancer Therapies: A Targeted Literature Review (TLR)
May 16, 2022
Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation
May 04, 2022
Treatment patterns among metastatic SS patients in The US Oncology Network
April 08, 2022
HSR22-141: Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small Cell Lung Cancer Patients Without Actionable Genomic Alterations (AGAs) Previously Treated With Platinum-Based Chemotherapy and Immunotherapy
March 31, 2022
Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small Cell Lung Cancer Patients Without Actionable Genomic Alterations (AGAs) Previously Treated With Platinum-Based Chemotherapy and Immunotherapy
March 31, 2022
Real-world clinical characteristics and management of breast cancer in patients with germline pathogenic variants in ATM, CHEK2, and PALB2
March 22, 2022
Health Care Services Burden in Ovarian Cancer Patients Receiving PARP Inhibitor Maintenance Treatment
March 18, 2022
Real-world treatment pattern and drop-off among previously treated recurrent or metastatic cervical cancer patients: a community oncology-based analysis
March 18, 2022
Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network
March 10, 2022
Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma
March 04, 2022
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting
February 16, 2022
Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network
January 29, 2022
Real-world outcomes among crizotinib-treated patients with ROS1-positive advanced non-small-cell lung cancer: a community oncology-based observational study
January 01, 2022
Real-world Outcomes Among Crizotinib-treated Patients Diagnosed with ROS1-Positive Advanced Non-Small Cell Lung Cancer: A Community Oncology-based Observational Study
December 29, 2021
Understanding Hematological Adverse Event Management through Health Care Resource Utilization, Costs, and Treatment Patterns of Patients with Extensive-Stage Small Cell Lung Cancer Treated in the Community Oncology Setting
December 11, 2021
Retrospective study of real-world treatment patterns and outcomes in advanced/metastatic renal cell carcinoma patients receiving lenvatinib/everolimus after heavy pretreatment
December 03, 2021
Risk of hospitalization and emergency room visits among community oncology patients
November 30, 2021
COVID-19 Pandemic impacts volume of Evaluation & Management (E&M) telehealth visits within community oncology practices
November 30, 2021
Results of self-reported EHR COVID screenings among community oncology patients
November 30, 2021
Monitoring of reported COVID-19 vaccination rates in community oncology settings
November 30, 2021
Characterization of unresectable and/or metastatic solid tumors patients treated with systemic anticancer therapy in first-line settings: A Pan-tumor community-oncology based study
November 10, 2021
The Friends of Cancer Research Real World Data (RWD) Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies
October 18, 2021
Real-world burden of myelosuppression among patients with extensive-stage small cell lung cancer treated in the community oncology setting
October 18, 2021
Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot
October 16, 2021
Real-world utilization and costs with biosimilar and reference filgrastim in patients with breast cancer receiving myelosuppressive chemotherapy in a community oncology setting from 2015 to 2017.
September 21, 2021
Adoption of immune checkpoint inhibitors (ICI) for unresectable locally advanced or metastatic urothelial carcinoma (u/mUC): A retrospective assessment of community oncology practices
September 21, 2021
Durvalumab Consolidation Therapy following Chemoradiotherapy among Patients with Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Treated in a US Community Oncology Network
September 21, 2021
Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab
September 21, 2021
Trends in molecular testing for metastatic non-small cell lung cancer in The US Oncology Network community practices (Abstract P60.11)
September 17, 2021
Clinical Trials in Progress: MYLUNG: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective Real World Evidence (RWE) Program. (Abstract P60.13)
September 17, 2021
Multi-omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial
September 12, 2021
Real-World Data Analysis of Second-Line Poly(ADP-ribose) Polymerase Inhibitor Maintenance Therapy in Patients With Advanced Ovarian Cancer
August 30, 2021
The Friends of Cancer Research Real World Data (RWD) Pilot 2.0 Collaboration: Implementation of Standardized Methodological Approaches for Evaluation of Oncology RWD
August 24, 2021
Outcomes in patients (pts) with advanced basal cell carcinoma (aBCC) who discontinued first-line (1L) hedgehog inhibitors (HHI) systemic treatment (Tx) in a US community oncology setting: A retrospective observational study
August 23, 2021
Frequency, characteristics, and subsequent treatment (Tx) of real-world patients (pts) who discontinue hedgehog inhibitors (HHIs) as first-line (1L) systemic Tx for advanced basal cell carcinoma (aBCC)
August 23, 2021
Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective study.
August 11, 2021
Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: a real-world retrospective observational study
July 01, 2021
Real-world clinical outcomes in patients with locally advanced or metastatic Merkel cell carcinoma treated in US oncology clinical practices: results from SPEAR-Merkel.
June 08, 2021
Evaluating real-world overall survival (rwOS) across oncology data sources: Friends of Cancer Research non-small cell lung cancer pilot study
June 04, 2021
Frequency, characteristics, and subsequent treatment (Tx) of real-world patients (pts) who discontinue hedgehog inhibitors (HHIs) as first-line (1L) systemic Tx for advanced basal cell carcinoma (aBCC)
June 04, 2021
Outcomes in patients (pts) with advanced basal cell carcinoma (aBCC) who discontinued hedgehog inhibitors (HHI) as first-line (1L) systemic treatment (Tx) in a U.S. community oncology setting: A retrospective observational study.
June 04, 2021
Real-world data analysis of the utilization of second-line maintenance therapy for patients with advanced ovarian cancer
June 04, 2021
Evolution of standard of care therapies used for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A real-world analysis of patient health records from 2016 to 2019
June 04, 2021
Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices
June 04, 2021
Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC)
June 04, 2021
Real-world patterns of biomarker testing and targeted therapy in metastatic non-small cell lung cancer (mNSCLC) in the community oncology setting
June 04, 2021
A natural language processing tool for automatic identification of new disease and disease progression: Parsing text in multi-institutional radiology reports to facilitate clinical trial eligibility screening
June 04, 2021
Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists
May 29, 2021
Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: a real-world retrospective observational study
May 24, 2021
Directly Comparing Randomized and Real-World Controls in Adjuvant Breast Cancer
May 17, 2021
Concordance of Clinical vs. Algorithm Based Line of Therapy Determination in Lung Cancer
May 17, 2021
Challenges in Estimating Sample Size for Retrospective Real-World Research
May 17, 2021
Real-world clinical effectiveness of lenvatinib/everolimus in a heavily pretreated advanced/metastatic renal cell carcinoma population in the US community oncology setting.
May 15, 2021
Treatment Patterns and Outcomes of Patients With Advanced Malignant Pleural Mesothelioma in a Community Practice Setting
March 26, 2021
Pembrolizumab utilization and clinical outcomes among patients with advanced melanoma in the US community oncology setting: An updated analysis
March 17, 2021
Real World Clinical Outcomes in Avelumab Treated Patients (Pts) in the US from SPEAR-Merkel - Study Informing Treatment Pathway DEcisions in Merkel Cell CARcinoma (MCC)
March 12, 2021
Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis
March 01, 2021
Recurrence Rates in Patients with HER2+ Breast Cancer Who Achieved a Pathological Complete Response after Neoadjuvant Pertuzumab plus Trastuzumab Followed by Adjuvant Trastuzumab: A Real-World Evidence Study
March 01, 2021
Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with mRCC
February 11, 2021
Comparisons of Real-World Time-to-Event End Points in Oncology Research
January 07, 2021
Retrospective observational study of ALK-inhibitor therapy sequencing and outcomes in patients with ALK-positive non-small cell lung cancer
December 07, 2020
Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study
December 02, 2020
Real-world outcomes of patients with resected stage IIIA melanoma treated with adjuvant nivolumab
November 11, 2020
An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF‐mutant advanced melanoma treated with first‐line anti‐PD‐1 monotherapies or BRAF/MEK inhibitors in a community‐based oncology setting
November 09, 2020
Treatment sequencing patterns in patients with metastatic urothelial cancer treated in the community practice setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR).
November 05, 2020
Real-world evidence-based patient profiles and treatment patterns among patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) from 2016-2019
October 21, 2020
Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy
October 09, 2020
Real-world clinical outcomes with pembrolizumab (pembro) for treatment of advanced melanoma: Evidence from the United States community oncology setting
September 19, 2020
Real-world outcomes in patients receiving nivolumab 480 mg every 4 weeks versus other dosing regimens as treatment for melanoma in the adjuvant setting
June 24, 2020
Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer
June 04, 2020
Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC): Analysis of real-world data
May 29, 2020
Treatment outcomes and healthcare resources utilization (HRU) among patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy in US community oncology setting
May 29, 2020
Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence
May 29, 2020
Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel Study informing treatment Pathway decisions in Merkel cell carcinoma (MCC)
May 29, 2020
Real-world (RW) systemic treatment patterns and clinical outcomes in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC) patients (PTS)
May 29, 2020
Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration
May 29, 2020
EARLY real-world treatment and dosing patterns of ribociclib for metastatic breast cancer (mBC): a retrospective observational study
May 29, 2020
Early physician spillover responses to the oncology care model
May 29, 2020
A real-world comparative analysis of pomalidomide (POM) and other antimyeloma treatments following lenalidomide (LEN) discontinuation among patients with multiple myeloma
May 29, 2020
Evaluation of practice patterns among oncologists participating in the Oncology Care Model
May 18, 2020
Drivers of new drug adoption in oncology
March 16, 2020
Concordance of death date assessments between the Social Security Death Master File and electronic health records in a US community oncology setting
March 16, 2020
Concordance of real-world time-to-event endpoints with clinical outcomes in oncology studies
March 16, 2020
Treatment patterns and healthcare resource utilization among patients with advanced or metastatic soft tissue sarcoma in US community practices
March 01, 2020
Real-world outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) who received first- or second-line immunotherapies (IO) in the United States (US).
February 13, 2020
Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
January 18, 2020
Biomarker testing rates in patients with advanced non-small cell lung cancer treated in the community
December 01, 2019
Outcomes of nivolumab (NIVO)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC) in United States community oncology practice.
November 06, 2019
Treatment Patterns and Outcomes of Advanced Malignant Pleural Mesothelioma (MPM) Patients in a Community Practice Setting
September 07, 2019
ALK inhibitor sequencing and outcomes among ALK-positive (ALK+) non-small cell lung cancer (NSCLC) patients in the US community oncology setting
September 07, 2019
Treatment patterns among patients with EGFRm NSCLC treated in the US community oncology setting
September 07, 2019
Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the US: A Retrospective Electronic Medical Record Database and Chart Review Study
August 24, 2019
Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: A retrospective, community oncology-based cohort study (A STROBE-compliant article)
July 01, 2019
Real-world patient profiles and clinical outcomes among patients with BRAF-positive advanced melanoma treated with first-line anti-PD1 monotherapies or BRAF+MEK inhibitor combination therapy in the United States (US) community oncology setting
June 20, 2019
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
June 07, 2019
Real-world outcomes of metastatic urothelial carcinoma (mUC) patients (pts) treated with first or second-line immunotherapies (IO) in the United States (US)
May 31, 2019
Treatment patterns and outcomes among patients with advanced cutaneous squamous cell carcinoma (CSCC) in a US community oncology setting
May 31, 2019
Retrospective Real-World Assessment of Response Outcomes in Oncology
May 18, 2019
Impact of EHR technology updates on patients' access to oncology drugs
May 18, 2019
Development of Playbook for chart review in real-world data
May 18, 2019
Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study
April 25, 2019
Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study
April 25, 2019
SPEAR-Bladder (Study informing treatment Pathway decision in bladder cAnceR): Influence of treatment sequencing on time to treatment failure and overall survival in the United States
February 14, 2019
A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting
January 11, 2019
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck
December 04, 2018
Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study
December 01, 2018
Safety of Split First Dosing vs Standard Dosing Administration of Daratumumab among Multiple Myeloma Patients Treated in a US Community Oncology Setting: A Real-World Observational Study
December 01, 2018
Real-world treatment patterns among advanced soft tissue sarcoma patients receiving systemic therapy in a community oncology setting in the United States
November 14, 2018
Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis
November 01, 2018
Patient profiles and treatment patterns among patients with advanced melanoma treated in the US community oncology setting: A retrospective, observational study
October 24, 2018
Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. Clin Breast Cancer
October 01, 2018
Outcomes among patients with EGFR-mutant metastatic NSCLC with and without brain metastases
September 23, 2018
Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting
June 26, 2018
SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR): first- through third-line time to treatment failure in the US
June 01, 2018
Adjuvant therapy utilization among stage III melanoma patients
June 01, 2018
Patient characteristics and treatment patterns from SPEAR-BLADDER: Study informing treatment Pathway decision in bladder cancer
May 19, 2018
Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study
May 01, 2018
Treatment patterns in HER2+/HR+ postmenopausal women with metastatic breast cancer initiating first-line treatment in a community oncology setting in the US
March 26, 2018
Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small Cell Lung Cancer Patients Treated in the Community Practice Setting
February 17, 2018
Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices
February 03, 2018
Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
February 01, 2018
Treatment Patterns and Clinical Outcomes in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated in the Community Practice Setting in the United States
February 01, 2018
Clinical Profiles, Treatment Characteristics and Outcomes among Newly Diagnosed Hodgkin lymphoma Patients Presenting with Unfavorable and Advanced Disease within a US Community Oncology Setting
December 09, 2017
MCL Treatment Patterns and Outcomes: A Community Oncology Practice Experience
December 09, 2017
Understanding Ibrutinib Treatment Discontinuation Patterns for Chronic Lymphocytic Leukemia
December 09, 2017
A Real-World Comparative Analysis of Carfilzomib and Other Systemic Multiple Myeloma Chemotherapies in the US Community Oncology Setting
December 09, 2017
Carfilzomib Dosing Patterns and Time to Next Treatment Among Adult Patients with Multiple Myeloma Treated in the US Community Oncology Setting
December 09, 2017
From angst to analytics: lessons learned from an oncology care model internal pilot
November 01, 2017
Real world utilization and outcomes of pembrolizumab for the treatment of patients with advanced melanoma in US community oncology practice
October 18, 2017
Predictive factors associated with ramucirumab monotherapy or combination therapy among patients with gastric/gastroesophageal junction cancer in the community oncology setting
June 28, 2017
Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice
June 28, 2017
Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
June 13, 2017
Real world treatment utilization and outcomes of patients with metastatic bladder cancer by cisplatin eligibility in US community oncology practice
June 02, 2017
Characteristics of adult multiple myeloma patients receiving carfilzomib in a US community oncology setting
June 02, 2017
Real-world treatment patterns of adult multiple myeloma patients treated with carfilzomib in the US community oncology setting
June 02, 2017
Treatment patterns in recurrent/metastatic head and neck squamous cell carcinoma in the US
June 02, 2017
Understanding treatment patterns and outcomes in patients with metastatic NSCLC treated in a US Community oncology network
June 02, 2017
An Observational Study of Patients with Advanced Melanoma Receiving Pembrolizumab in Real World US Community Oncology Practice
June 02, 2017
Treatment outcomes with first-line (1L) nab-Paclitaxel + gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma ASCO
June 02, 2017
Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer
April 26, 2017
Chemotherapy costs, but not resource utilization, are inversely correlated with the primary platinum-free interval among outpatients with recurrent ovarian cancer
March 15, 2017
HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes
March 01, 2017
Management of elderly patients with diffuse large B-cell lymphoma in a network of community oncology practices in the United States
December 03, 2016
Real-world outcomes of patients with metastatic merkel cell carcinoma treated with second-line or later chemotherapy in a community oncology setting in the United States
October 29, 2016
Treatment patterns, clinical outcomes, and health care resource utilization in patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NETs)
September 30, 2016
Early treatment utilization of palbociclib for metastatic breast cancer (MBC) in a U.S. community oncology network
June 03, 2016
Real-world use of first-line chemotherapy in post-menopausal patients with HR-positive HER2-negative metastatic breast cancer (mBC) in a US community oncology network
June 03, 2016
Sustained impact of primary platinum-free interval and BRCA1/2 mutation status on survival in patients with ovarian cancer after multiple lines of therapy
June 03, 2016
Treatment patterns and clinical outcomes in pazopanib compared to sunitinib as first line therapy for patients with advanced/metastatic renal cell carcinoma (aRCC) in a US community oncology setting
May 21, 2016
Real world treatment patterns and outcomes in HER2 positive MBC patients with brain metastasis in the US community oncology setting
February 26, 2016
Treatment patterns and clinical outcomes of patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NETs)
January 21, 2016
Axitinib treatment among patients with mRCC in a U.S. community oncology setting: A retrospective study of 135 patients
January 07, 2016
Comparative effectiveness of pazopanib and sunitinib as first line therapy for patients with advanced/metastatic renal cell carcinoma in a US community oncology setting
January 07, 2016
Pertuzumab (P) use in first-line HER2-positive metastatic breast cancer (mBC) in US community oncology practices: Treatment patterns and outcomes
December 08, 2015
Carfilzomib dosing patterns and survival in patients with relapsed and refractory multiple myeloma: an analysis from US community oncology practices
December 05, 2015
Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices.
November 01, 2015
Clinical characteristics, treatment patterns, and outcomes for patients with HER2-positive metastatic breast cancer treated with pertuzumab in the first-line in a real-world setting
September 25, 2015
The effectiveness of tyrosine kinase inhibitors and molecular monitoring patterns in newly diagnosed patients with chronic myeloid leukemia in the community setting
June 18, 2015
Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma
May 18, 2015
Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices
March 15, 2015
Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based us oncology practices
January 08, 2015
First-line and sequential use of pazopanib followed by mammalian target of rapamycin inhibitor therapy among patients with advanced renal cell carcinoma in a US community oncology setting
November 14, 2014
A real-world observational study of patients with advanced melanoma receiving first-line ipilimumab in a community practice setting
October 01, 2014
Outcomes of advanced renal cell carcinoma patients (aRCC) treated with first-line pazopanib (PAZ) in a US community oncology setting
September 26, 2014
Outcomes of advanced renal cell carcinoma patients (aRCC) treated with mammalian target of rapamycin inhibitor (mTORi) therapy following first-line pazopanib (PAZ) in a US Community Oncology Setting
September 26, 2014
Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices
June 21, 2014
Treatment of patients (pts) with HER2- metastatic breast cancer (MBC) with nab-paclitaxel (nab-P) in the clinical practice setting: Results of a US Oncology survey
May 31, 2014
Real-world safety and efficacy of nab-paclitaxel in patients with metastatic breast cancer (mBC) treated in the united states: results from a health insurance database
May 31, 2014
Bridging to survivorship in breast cancer: How BMI weighs in
May 31, 2014
Treatment patterns and outcomes in metastatic colorectal cancer (mCRC) patients treated in a community oncology setting
May 31, 2014
Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network
January 12, 2014
Opening the black box: the impact of an oncology management program consisting of level I pathways and an outbound nurse call system
January 01, 2014
Dose delays, dose reductions, and relative dose intensity in early stage breast cancer patients receiving (neo)adjuvant chemotherapy in community oncology practices
December 10, 2013
Retrospective analysis of long-term survivors with HER2+ metastatic breast cancer (MBC) treated with trastuzumab in a community setting
December 10, 2013
Relative dose intensity of taxane-based chemotherapy in patients with stage IV breast cancer
December 10, 2013
Impact of route of bortezomib (B) administration on dose intensity and time to dose reduction in previously untreated patients (pts) With multiple myeloma (MM)
December 07, 2013
Comparable outcomes with bortezomib-cyclophosphamide-dexamethasone (VCD) and bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM)
December 07, 2013
Association between treatment adherence and response among patients with chronic myeloid leukemia (CML) receiving first-line TKIs in the community setting
December 07, 2013
Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network
December 01, 2013
Assessment of physician compliance to liver function test monitoring guidance for patients treated with lapatinib
September 01, 2013
Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer
July 01, 2013
Treatment patterns, biomarker testing, and outcomes in patients with nonsquamous non-small cell lung cancer (NSCLC) receiving second-line treatment in the US Oncology network
May 31, 2013
Types, frequency, and adherence of molecular tests in chronic myelogenous leukemia at chronic phase (CML-CP) in the U.S. community setting
May 31, 2013
Use of an electronic health record (iKnowMed), in conjunction with evidence-based pathways, for data capture and outcome measurement in colorectal cancer patients treated with first-line therapy in the US Oncology Network
May 31, 2013
Bridging to survivorship in breast cancer: Learning how treatment impacts mental health among early-stage breast cancer survivors
May 31, 2013
Impact of pathways on chemotherapy administration before death
May 31, 2013
Evaluation of survival outcomes in select first-line treatment regimens for advanced nonsquamous non-small cell lung cancer patients
May 18, 2013
Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study
February 25, 2013
Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
February 14, 2013
Rates of guideline adherence among US community oncologists treating NSCLC
January 01, 2013
Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology
December 01, 2012
Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network
October 16, 2012
Sunitinib dosing, toxicity, and outcomes in first-line advanced renal cell carcinoma (aRCC): A U.S. Oncology Network (USON) retrospective study
June 01, 2012
Treatment practice patterns and survival among patients with metastatic soft tissue sarcoma (mSTS) in a community setting in the United States
June 01, 2012
Retrospective data study evaluating resource utilization among metastatic renal cell carcinoma patients receiving oral versus intravenous mTOR inhibitors
June 01, 2012
Retrospective observational study: Bevacizumab (B) use and outcomes among metastatic colorectal cancer (mCRC) patients (pts) receiving care in the outpatient community in the United States
January 19, 2012
Demographics, treatment patterns, safety, and real-world effectiveness in patients ≥70 years of age with chronic lymphocytic leukemia receiving bendamustine with or without rituximab
December 10, 2011
Economic impact of disease progression in follicular non-Hodgkin lymphoma
November 01, 2011
Utilization of pegfilgrastim in adjuvant chemotherapy regimens for breast cancer in the community
September 08, 2011
Patterns of care and patient characteristics in postmenopausal women with HER2+ and hormone receptor-positive (HR+) metastatic breast cancer (MBC)
June 03, 2011
Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab-containing regimen
June 03, 2011
Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community
June 03, 2011
Bevacizumab therapy in advanced non-small cell lung cancer (NSCLC): Outcomes from a community oncology network
June 03, 2011
Evaluation of relation between Oncotype DX recurrence score and adjuvant chemotherapy administration
June 03, 2011
Demographic and treatment characteristics for advanced basal cell carcinoma (aBCC) in an oncology outpatient setting
June 03, 2011
Understanding male breast cancer in the community setting
June 03, 2011
Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer
June 03, 2011
Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases
May 01, 2011
Economic impact of disease progression in follicular non-hodgkin's lymphoma
December 04, 2010
Economic outcomes among 2nd line non-small cell lung cancer patients in the outpatient community setting
November 06, 2010
Bevacizumab (BV) treatment (Tx) to progression (BTP): outcomes from a US community practice network
October 08, 2010
Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network
June 04, 2010
First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting
June 04, 2010
Observational study evaluating resource utilization among metastatic renal cell carcinoma patients treated with mTOR inhibitors in the outpatient community-based setting
June 04, 2010
Impact of comorbidities on clinical and economic outcomes among patients with advanced non-small cell lung cancer (NSCLC) receiving care in the community-based outpatient setting
June 04, 2010
Evaluation of the reliability of electronic medical record data in identifying co-morbid conditions among patients with advanced NSCLC
May 15, 2010
Cost-effectiveness of 1st line chemotherapy regimens in the treatment of NSCLC among patients receiving care in the outpatient community setting
May 15, 2010
Clinical outcomes of 2nd line advanced NSCLC patients receiving monotherapy in the outpatient community setting
April 28, 2010
Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting
January 01, 2010
Variability of flow cytometry screening for paroxysmal nocturnal hemoglobinuria in five community based oncology practices
October 16, 2009
First-line trastuzumab utilization: Patterns of care and progression in the community setting
May 29, 2009
An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma
June 08, 2008
Cost analysis of immunoglobulin prophylaxis in lymphocytic leukemia
May 03, 2008
From angst to analytics: lessons learned from an oncology care model internal pilot
July 09, 2005
Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
July 09, 2005
Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based us oncology practices
July 07, 2005
A real-world observational study of patients with advanced melanoma receiving first-line ipilimumab in a community practice setting
July 06, 2005
Rates of guideline adherence among US community oncologists treating NSCLC
July 05, 2005
Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study
July 05, 2005
Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting
July 02, 2005
top
Contact Us
close